Novo has burst into the limelight over the last two years after Wegovy and sister diabetes drug Ozempic were found to induce significant weight loss for people, with celebrities and high profile business personalities openly discussing their use of them. The popularity of the medicines has led to supply shortages and delays in launching the drugs in new markets.
The agency also recently asked Novo for more data on the potential link between its GLP-1 hormone and thyroid cancer. In Wegovy’s safety information, the medication lists a potential risk of thyroid cancer, and people with a family history of certain serious conditions are advised not to take it. Patients may also experience inflammation of the pancreas or kidney injury.Article content
“GLP-1 receptor agonists have been used to treat type 2 diabetes for more than 15 years and for treatment of obesity for eight years, including Novo products such as semaglutide and liraglutide that have been on the market for more than 10 years,” a spokesperson for the company said.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: GlobalNational - 🏆 81. / 51 Read more »
Source: globeandmail - 🏆 5. / 92 Read more »
Source: tbnewswatch - 🏆 75. / 51 Read more »
Source: globeandmail - 🏆 5. / 92 Read more »
Source: TSN_Sports - 🏆 80. / 51 Read more »
Source: tbnewswatch - 🏆 75. / 51 Read more »